Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCrimson Tide Regulatory News (TIDE)

Share Price Information for Crimson Tide (TIDE)

Share Price is delayed by 15 minutes
Get Live Data
87.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 5.00 (5.882%)
Market Cap: £5.75m
TIDE Live PriceLast checked at - London Stock Exchange

Intraday Crimson Tide Share Chart

Pharmaceutical Verification Pilot

14 Jul 2016 07:00

RNS Number : 1316E
Crimson Tide PLC
14 July 2016
 

Crimson Tide PLC

 

("Crimson Tide" or the 'Company')

 

Crimson Tide selected for pharmaceutical verification pilot

 

Crimson Tide (TIDE), the AIM-quoted provider of mpro5 - Smart Mobility as a Service, has won a contract for the initial stage of a significant healthcare pilot project in Asia for the serialisation and verification of pharmaceutical products. The pilot project is being implemented under the auspices of the Asia Pacific Economic Cooperation (APEC) Life Sciences Innovation Forum (LSIF), Committee on Trade and Investment (CTI) and Business Advisory Council (ABAC).

 

Selected by a consortium of pharma organisations, the technology platform for the demonstration phase of the pilot project will leverage mpro5 to scan pharmaceutical products, generating an anonymous verification request to the product's manufacturer. The pilot project seeks to demonstrate for the first time the ability to verify serialised pharmaceutical products from various scan locations to source data stored in distributed databases using global data standards. The pilot also seeks to promote harmonisation by demonstrating the ability to use a single or reproducible data gateway in multiple countries.

 

mpro5 provides barcode scanning and cloud-based synchronisation services via Microsoft Azure, renowned for its reliability, scalability and security. This enables real-time information upload, quick verifications and multi-way data request transmittals.

 

Barrie Whipp, Executive Chairman of Crimson Tide, said: "The global impact of drug serialisation and verification cannot be underestimated. I am delighted that we have been chosen to help in this pilot project in Asia, as it opens up significant opportunities in the pharma world."

 

ends

 

For further information:

 

Crimson Tide plc

 

Barrie Whipp 01892 542 444

Steve Goodwin

 

WH Ireland

 

James Joyce /James Bavister 020 7220 1666

Allerton Communications

Peter Curtain 020 3137 2500

peter.curtain@allertoncomms.co.uk 

 

Notes to editors

Founded in 1996 and quoted on AIM since 2006, Crimson Tide plc is the provider of mpro5 - Smart Mobility as a Service (SMaaS). mpro5 is delivered on smartphones, tablets and PDAs, and enables companies to transform their businesses and strengthen their workforces.

Crimson Tide offers a global service, working with some of the world's leading companies, tailoring mpro5 to suit customer needs. Developed over 10 years by its world-class team, mpro5 is the smart choice for organisations large and small that want to improve productivity and save money.

mpro5 is a platform-agnostic mobility suite fully hosted on Microsoft Azure, so customers are quickly up and running and the service is scalable and robust. It is provided on subscription, so clients can immediately see a return on their investment.

mpro5 not only helps people improve their day-to-day working methods while saving employers money, it also saves lives, by enabling haemophilia patients to verify the safety of their medication before use. mpro5 clients come from a diverse range of industries allowing the Company to listen, share and find the best solution for all mobility needs.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTEAPXDFFLKEFF
Date   Source Headline
18th Nov 20169:45 amRNSDirector/PDMR Shareholding
13th Oct 20167:00 amRNSSignificant long term contract win
12th Oct 20167:00 amRNSLong Term Contract with NCHCD
22nd Sep 20167:00 amRNSInterim Results
18th Jul 20167:00 amRNSCrimson Tide selected by large UK retailer
14th Jul 20167:00 amRNSPharmaceutical Verification Pilot
29th Jun 20168:31 amRNSResult of AGM
14th Jun 20167:00 amRNSMpro5 Contract Win
3rd Jun 20163:47 pmRNSFinal Results and Notice of AGM
20th May 20163:26 pmRNSExercise of Options
20th Apr 20167:00 amRNSPreliminary Results
25th Feb 20167:00 amRNSTrading Update
24th Feb 20163:34 pmRNSResult of Court Hearing
26th Jan 20162:37 pmRNSResult of General Meeting
30th Dec 20157:00 amRNSProposed Reconstruction of Capital
4th Dec 20157:00 amRNSUpdate on Significant Contract Win
7th Oct 20155:58 pmRNSHolding(s) in Company
1st Oct 20152:45 pmRNSDirector's Dealing
30th Sep 20157:00 amRNSInterim Results
17th Sep 20157:00 amRNSSignificant contract win
1st Jul 20157:00 amRNSResult of AGM
8th Jun 20157:00 amRNSFinal Results and Notice of AGM
4th Jun 20157:00 amRNSSignificant Contract Win
14th Apr 20157:00 amRNSContracts Update
2nd Apr 20157:00 amRNSPreliminary Results
20th Mar 201510:03 amRNSDirectorate Change
3rd Mar 20157:00 amRNSTrading Update
24th Feb 20157:00 amRNSNew Finance Facilities
30th Jan 20155:02 pmRNSHolding(s) in Company
11th Dec 20147:00 amRNSAppointment of Director
29th Oct 20147:00 amRNSContract win for mpro5
14th Oct 20147:00 amRNSContract win for mpro
23rd Sep 20147:00 amRNSInterim Results
1st Sep 20147:00 amRNSSignificant contract win takes Crimson Tide Global
23rd Jul 20142:28 pmRNSHolding(s) in Company
5th Jun 20144:30 pmRNSDirector's Dealing
4th Jun 20147:00 amRNSContract Extensions for MPRO5 worth over £200k
30th May 20145:35 pmRNSFinal Results and Notice of AGM
10th Apr 20148:56 amRNSHolding(s) in Company
2nd Apr 20147:00 amRNSPreliminary Results
10th Mar 20147:00 amRNSStrategic Partnership Agreement
30th Oct 201311:22 amRNSTR-1: Notification of major interest in shares
29th Oct 20137:00 amRNSContract Extension
20th Sep 20137:05 amRNSNew Contract Wins
20th Sep 20137:00 amRNSInterim Results
17th Sep 20137:00 amRNSContract Extension
23rd Aug 20132:20 pmRNSChange of responsibilities
28th Jun 20133:23 pmRNSResult of AGM
6th Jun 20137:00 amRNSFinal Accounts and AGM
23rd May 20137:00 amRNSThree New Contract Wins

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.